Skip to main content

Table 1 Patient demographic and baseline characteristics (full analysis set, N=30)

From: Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy

Characteristics n %
Male/female ratio 26/4 86.7:13.3
Age (years)
 Median (range) 60 (32–72)  
 > 65 5 16.7
ECOG performance status
 0 3 10.0
 1 27 90.0
TNM stage
 IV 30 100
CEA(ng/ml)
 < 5 2 6.7
 5–200 16 53.3
 > 200 10 33.3
 Unknown 2 6.7
Primary disease site
 Colon 13 43.3
 Rectum 16 53.3
 Colon and rectum 1 3.3
Primary tumor location
 Right 4 13.3
 Left colon and rectum 26 86.7
Primary tumor resected
 Yes 19 63.3
 No 11 36.7
Metastatic sites
 Liver only 16 53.3
 Liver + other 9 30
 Other only 5 16.7
Metastatic status
 Synchronous 25 83.3
 Metachronous 5 16.7
Diameter of the largest target lesions (mm)
 median (range)a 45 (16–122)  
MSI/MMR statusb
 MSS/pMMR 25 83.3
 MSI-H/dMMR 0 0
 Unknow 5 16.7
  1. ECOG, Eastern Cooperative Oncology Group; TNM, tumor, node, metastasis; CEA, carcinoembryonic antigen; MSI, micro satellite instability; MMR, mismatch repair
  2. aThe median is determined by IQR
  3. bThirteen patients received the MSI test by PCR and MMR test by immunohistochemistry, and 9 patients only received the MMR test by immunohistochemistry and 3 patients only received MSI test by PCR